TCGA-XF-A9T5-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 66.59001314
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- ALLOGRAFT_REJECTION+0.570
- INTERFERON_GAMMA_RESPONSE+0.560
- E2F_TARGETS+0.500
- MYC_TARGETS_V1+0.480
- OXIDATIVE_PHOSPHORYLATION+0.480
- MYC_TARGETS_V2+0.420
- IL6_JAK_STAT3_SIGNALING+0.380
- G2M_CHECKPOINT+0.360
- MTORC1_SIGNALING+0.330
Top 10 suppressed
- TGF_BETA_SIGNALING-0.460
- PROTEIN_SECRETION-0.330
- UV_RESPONSE_DN-0.320
- MITOTIC_SPINDLE-0.190
- BILE_ACID_METABOLISM-0.160
- MYOGENESIS-0.160
- CHOLESTEROL_HOMEOSTASIS-0.120
- ESTROGEN_RESPONSE_EARLY-0.120
- PEROXISOME-0.120
- ANDROGEN_RESPONSE-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_02_0048_A10_S104 | — | C | 0.870 |
| 2 | TCGA-C8-A12K-01A-21R-A115-07 | — | E | 0.869 |
| 3 | BS_996ZS2A4 | ATRT | — | 0.863 |
| 4 | MNG921 | — | — | 0.852 |
| 5 | TCGA-22-4599-01A-01R-1443-07 | — | cohortSQ2 | 0.849 |
| 6 | R261 | — | — | 0.844 |
| 7 | TCGA-AR-A1AQ-01A-11R-A12P-07 | — | E | 0.842 |
| 8 | TCGA-C8-A1HF-01A-11R-A137-07 | — | C | 0.839 |
| 9 | SRR8518316 | — | D | 0.834 |
| 10 | MNG742 | — | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |